Finally, we analyzed TBX1 and its target genes, identified here using gene expression profiling dataset GSE44589, which covers 198 CML patients prior to and after treatment with ABL1-inhibitor imatinib. Here, TBX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.